This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
A Pureplay ETF on Leisure from SonicShares in the Offing
by Sanghamitra Saha
SonicShares recently filed for an Airlines, Hotels, Cruise Lines ETF.
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
The passage of the $1.9 trillion COVID-19 relief bill and tame inflation data boosted the markets last week.
6 Top Leveraged ETF Areas of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones, the Nasdaq Composite and the small-cap Russell 2000 were all on an uptrend last week.
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.
Company News for Mar 15, 2021
by Zacks Equity Research
Companies in the news are: CNTY, DS, EBON, NVAX
Novavax ETFs to Shine Bright on Positive Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development and distribution amid the pandemic.
5 Stocks to Watch Amid Continued Expansion in the Biotech Industry
by Kaustav Ghosh
The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)
Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?
by Kevin Cook
New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.
Haverty Furniture, Noodles & Co, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Haverty Furniture, Noodles & Co, Novavax and Zoom Video highlighted as Zacks Bull and Bear of the Day
Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates
by Zacks Equity Research
Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.
Markets Up Big Monday; Zoom (ZM) Beats, Novavax (NVAX) Misses Q4
by Mark Vickery
The Dow rose 1.95% on the day, +603 points; the S&P 500 gained 2.38%; the Nasdaq rose 3%, nearly 400 points; and the small-cap Russell 2000 took the cake, +3.37%.
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed the most recent trading day at $243.23, moving -0.76% from the previous trading session.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Earnings Preview: Novavax (NVAX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge Fund Diaries: Who Was Buying Your Stocks?
by Kevin Cook
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
Are Stocks Too Hot to Buy?
by Tracey Ryniec
Lots of investors chased the big gains in the WSB/Reddit trades, but those stocks aren't the only ones that are soaring. How do you keep your cool in this red-hot market?
Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA
by Zacks Equity Research
Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
by Zacks Equity Research
Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $264.41 in the latest trading session, marking a -1.45% move from the prior day.